BTIG raised the firm’s price target on Masimo (MASI) to $200 from $198 and keeps a Buy rating on the shares after the company’s Investor Day presentation. The firm is positive on the company’s potential to be one of the most consistent performers in MedTech over the coming years, the analyst tells investors in a research note. BTIG adds that it likes that the company will continue to invest in next-gen sensors and monitors in a market that has seen minimal product innovation from competitors and believes it will allow the company to achieve sustainable high single digit growth during and beyond the Long Range Plan.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MASI:
- Masimo’s Growth Potential and Uncertainties: A Hold Rating Amidst Promising Innovations and Market Challenges
- Masimo’s Strategic Realignment and Transitional Growth: A Hold Rating Amidst Promising Long-term Targets
- Masimo Unveils Long-Term Strategy at Investor Day
- Masimo Secures New $1 Billion Credit Facility
- Masimo’s Strategic Shift and Valuation Concerns Lead to Hold Rating